Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.43 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27259214 | 0.87 | SIGMAR1 (0.56) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL18871388 | 0.86 | SIGMAR1 (0.57) | SIGMAR1ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL18118428 | 0.85 | ALDH1A1 (0.53) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL4578879 | 0.85 | SIGMAR1 (0.55) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL5095076 | 0.85 | SIGMAR1 (0.55) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL15834506 | 0.85 | ALDH1A1 (0.53) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL10223654 | 0.85 | ALDH1A1 (0.74) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL8434592 | 0.85 | SIGMAR1 (0.54) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL47686 | 0.84 | ALDH1A1 (0.49) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 | |
| SCHEMBL18623944 | 0.84 | SIGMAR1 (0.54) | SIGMAR1ALDH1A1KDM4ETDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-8492163-B2 | Methods, mixtures, kits and compositions pertaining to analyte determination | DH TECHNOLOGIES DEVELOPMENT PTE. LTD. (SG) | 2013-07-23 | — | — | US | disclosed |
| US-8329726-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-12-11 | — | — | US | disclosed |
| EP-2518067-A1 | Derivatives of N-[(1H-pyrazol-1-YL)aryl]-1H-indole or 1H- indazole-3-carboxamide and their therapeutic uses as P2Y12 antagonists | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| US-20120196378-A1 | Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination | DH TECHNOLOGIES DEVELOPMNET PTE LTD. (SI) | 2012-08-02 | — | — | US | disclosed |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC. | 2012-04-05 | — | — | US | disclosed |
| US-8093264-B2 | Fused heterocycles as inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2012-01-10 | — | — | US | disclosed |
| US-7906341-B2 | Isobaric sets, mass differential labeling sets; mass spectrometry | DH TECHNOLOGIES DEVELOPMENT PTE, LTD. (SG) | 2011-03-15 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080241955-A1 | Methods, Mixtures, Kits And Compositions Pertaining To Analyte Determination | APPLERA CORPORATION (US) | 2008-10-02 | — | — | US | disclosed |
| US-20080132500-A1 | Antibiotic compounds | MERCK SHARP & DOHME CORP. | 2008-06-05 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | SIGMAR1 2096/4885ALDH1A1 1649/4885KDM4E 4094/4885 |
| US-20120083482-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, KDR | SIGMAR1 650/4885ALDH1A1 411/4885KDM4E 4651/4885 |
| US-20080241955-A1 | Methods, Mixtures, Kits And Compositions Pertaining To Analyte Determination | SRMS, KLK3, MPO | SIGMAR1 4448/4885ALDH1A1 130/4885KDM4E 3783/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | SIGMAR1 4683/4885ALDH1A1 3553/4885KDM4E 840/4885 |
| US-20120196378-A1 | Methods, Mixtures, Kits and Compositions Pertaining to Analyte Determination | SRMS, KLK3, MPO | SIGMAR1 4448/4885ALDH1A1 130/4885KDM4E 3783/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | SIGMAR1 3727/4885ALDH1A1 3139/4885KDM4E 2282/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | SIGMAR1 3727/4885ALDH1A1 3139/4885KDM4E 2282/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | SIGMAR1 4190/4885ALDH1A1 2765/4885KDM4E 3392/4885 |
| US-20080132500-A1 | Antibiotic compounds | NRDC, MRPL21, PEPD | SIGMAR1 2910/4885ALDH1A1 3691/4885KDM4E 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.